The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is a single arm study to access the anti-tumor efficacy and safety of Andamertinib plus Anlotinib in patients with locally advanced or metastatic non-small cell lung cancer previously treated with third-generation EGFR-TKI.
Epistemonikos ID: d4382e8b80b98fef52c551dfde3d8a47ea2376be
First added on: Aug 21, 2026